Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de ustekinumab en participantes pediátricos con enfermedad de Crohn activa de moderada a grave (UNITI Jr)

2 de julio de 2026 actualizado por: Janssen Research & Development, LLC

Un estudio de fase 3 de la eficacia, seguridad y farmacocinética de ustekinumab como tratamiento de inducción intravenoso de etiqueta abierta seguido de mantenimiento de ustekinumab subcutáneo doble ciego aleatorizado en participantes pediátricos con enfermedad de Crohn activa de moderada a grave

El propósito de este estudio es evaluar la eficacia de la dosificación de ustekinumab para inducir la remisión clínica (Global) y mantener la remisión clínica (EE. UU.); evaluar el perfil de seguridad y la exposición a ustekinumab (farmacocinética [PK]) en participantes pediátricos con enfermedad de Crohn activa de moderada a grave.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

101

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Aachen, Alemania, 52074
        • Universitätsklinikum Aachen
      • Berlin, Alemania, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, Alemania, 45147
        • Universitätsklinikum Essen
      • Hanover, Alemania, 30625
        • Medizinische Hochschule Hannover
      • Munich, Alemania, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, Alemania, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, Alemania, 89075
        • Universitätsklinikum Ulm
      • Brussels, Bélgica, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, Bélgica, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, Bélgica, 9000
        • UZ Gent
      • Jette, Bélgica, 1090
        • UZ Brussel
      • Leuven, Bélgica, 3000
        • UZ Leuven
    • Delaware
      • Wilmington, Delaware, Estados Unidos, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Pediatric Specialists Of Virginia
      • Budapest, Hungría, 1083
        • Semmelweis Egyetem
      • Debrecen, Hungría, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, Hungría, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, Hungría, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, Hungría, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
      • Be’er Ya‘aqov, Israel, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, Israel, 4920235
        • Schneider Children's Medical Center
      • Bunkyō City, Japón, 113 8431
        • Juntendo University Hospital
      • Gunma, Japón, 371-0034
        • Gunma University Hospital
      • Ikoma, Japón, 630-0293
        • Kindai University Nara Hospital
      • Kurume, Japón, 830-0011
        • Kurume University Hospital
      • Saitama Shi, Japón, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, Japón, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, Japón, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, Japón, 329-0498
        • Jichi Medical University Hospital
      • Tsu, Japón, 514 8507
        • Mie University Hospital
      • Gdansk, Polonia, 80 803
        • Szpital im. M. Kopernika
      • Krakow, Polonia, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, Polonia, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polonia, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polonia, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Birmingham, Reino Unido, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Reino Unido, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, Reino Unido, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, Reino Unido, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, Reino Unido, E1 2AT
        • Royal London Hospital
      • Kazan', Rusia, 420138
        • Kazan State Medical University
      • Moscow, Rusia, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, Rusia, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, Rusia, 150032
        • Yaroslavl Regional Children's Clinical Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Descripción

Criterios de inclusión:

  • Tiene enfermedad de Crohn o enfermedad de Crohn fistulizante con colitis activa, ileítis o ileocolitis, confirmada en cualquier momento en el pasado mediante endoscopia e histología.
  • Debe tener enfermedad de Crohn activa de moderada a grave (según lo definido por una puntuación inicial del Índice de actividad de la enfermedad de Crohn pediátrica [PCDAI] superior a [>] 30); someterse a una ileocolonoscopia con evidencia de enfermedad de Crohn activa definida como la presencia de ulceración (que es igual a la puntuación endoscópica simple para la enfermedad de Crohn [SES-CD] mayor o igual a [>=] 3) durante la selección para este estudio. El procedimiento de ileocolonoscopia debe ocurrir dentro de aproximadamente 3 semanas antes de la administración de la intervención del estudio en la semana 0 (período de inducción). Se puede usar una videoileocolonoscopia grabada dentro de los 3 meses anteriores a la visita de la semana 0 (período de inducción) en caso de que se vuelva a evaluar a un participante que se sometió a una ileocolonoscopia pero no pasó la evaluación inicial por otro motivo, caso por caso, después de consulta con el patrocinador. Si no se puede evaluar la ulceración debido a estenosis o preparación intestinal inadecuada, se puede aplicar al menos uno de los siguientes criterios: una proteína C reactiva (PCR) anormal (> 0,3 miligramos por decilitro [mg/dL] o 3,0 miligramos por litro [mg/L] en la selección) o; calprotectina fecal de >= 250 miligramos por kilogramo [mg/kg] o >= 250 microgramos por gramo [mcg/g] en la selección
  • Si recibe nutrición enteral, debe haber estado en un régimen estable durante al menos 2 semanas antes de la semana de inducción 0 (Semana I-0)
  • Las mujeres en edad fértil deben tener una prueba de embarazo en orina de alta sensibilidad negativa en la selección y en la Semana I-0 antes de la administración de la intervención del estudio.

Criterio de exclusión:

  • Tiene complicaciones de la enfermedad de Crohn, como estenosis o estenosis sintomáticas, síndrome de intestino corto o cualquier otra manifestación que pueda anticiparse que requiera cirugía, que podría impedir el uso del PCDAI para evaluar la respuesta a la terapia o posiblemente confundiría la capacidad de evaluar la efecto del tratamiento con ustekinumab
  • Tener antecedentes de infección granulomatosa latente o activa, histoplasmosis o coccidioidomicosis, o haber tenido una infección por micobacterias no tuberculosas antes de la selección
  • Presencia o antecedentes de cualquier neoplasia maligna, incluida la presencia o antecedentes de enfermedad linfoproliferativa, incluido el linfoma, o signos y síntomas que sugieran una posible enfermedad linfoproliferativa, como linfadenopatía de tamaño o ubicación inusuales (por ejemplo, ganglios en el triángulo posterior del cuello, infraclavicular, epitroclear, o áreas periaórticas), y gammapatía monoclonal de significado indeterminado, o hepatomegalia o esplenomegalia clínicamente significativa
  • Tener antecedentes de insuficiencia hepática o renal moderada o grave progresiva o no controlada; o trastornos cardíacos, vasculares, pulmonares, gastrointestinales, endocrinos, neurológicos, hematológicos, psiquiátricos (incluidas las tendencias suicidas) o metabólicos significativos
  • Recibió una intervención en investigación que incluye vacunas en investigación o usó un dispositivo médico invasivo en investigación dentro de los 3 meses anteriores a la primera dosis planificada de la intervención del estudio o está actualmente inscrito en un estudio de investigación; recibir una vacuna en investigación para la enfermedad por coronavirus 2019 (COVID-19) no es un criterio de exclusión automático

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Etiqueta abierta Ustekinumab intravenoso (IV): Período de inducción
Todos los participantes recibirán una sola administración IV de ustekinumab en la semana de inducción 0 (I-0) según el área de superficie corporal (BSA) (miligramos por metro cuadrado [mg/m^2]) o la dosis de inducción según el peso (miligramos por kilogramo). [mg/kg]).
Ustekinumab se administrará por vía intravenosa en periodo de inducción y por vía subcutánea en periodo de mantenimiento.
Experimental: Ustekinumab subcutáneo (SC) cada 8 semanas (q8w): Período de mantenimiento
Los participantes recibirán la administración SC de ustekinumab q8w según el BSA (mg/m^2) o la dosis de inducción según el peso (mg/kg) en las semanas de mantenimiento (Semanas M)-0, M-8, M-16, M-24 , M 32 y M-40 y placebo correspondiente en las semanas M-12 y M-36 para mantener el ciego.
Ustekinumab se administrará por vía intravenosa en periodo de inducción y por vía subcutánea en periodo de mantenimiento.
El placebo correspondiente se administrará como inyección SC.
Experimental: Ustekinumab SC cada 12 semanas (q12w): Período de mantenimiento
Los participantes recibirán la administración SC de ustekinumab cada 12 semanas según el BSA (mg/m^2) o la dosis de inducción según el peso (mg/kg) en las semanas M-0, M-12, M-24, M-36 y el placebo correspondiente en Semanas M-8, M-16, M-32 y M-40 para mantener la persiana.
Ustekinumab se administrará por vía intravenosa en periodo de inducción y por vía subcutánea en periodo de mantenimiento.
El placebo correspondiente se administrará como inyección SC.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Periodo de tiempo: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Periodo de tiempo: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Periodo de tiempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Periodo de tiempo: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Periodo de tiempo: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Periodo de tiempo: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Periodo de tiempo: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Periodo de tiempo: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Periodo de tiempo: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Periodo de tiempo: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Periodo de tiempo: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Periodo de tiempo: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Periodo de tiempo: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de abril de 2021

Finalización primaria (Actual)

28 de noviembre de 2024

Finalización del estudio (Actual)

3 de marzo de 2025

Fechas de registro del estudio

Enviado por primera vez

14 de diciembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

14 de diciembre de 2020

Publicado por primera vez (Actual)

17 de diciembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • CR108864
  • 2019-004225-24 (Número EudraCT)
  • CNTO1275CRD3004 (Otro identificador: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (Identificador de registro: EUCT number)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

La política de intercambio de datos de Janssen Pharmaceutical Companies of Johnson & Johnson está disponible en www.janssen.com/clinical-trials/transparency. Como se indica en este sitio, las solicitudes de acceso a los datos del estudio se pueden enviar a través del sitio del proyecto Yale Open Data Access (YODA) en yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir